The 5-part program will dive deep into cultivation, extraction, processing, testing, third-party certifications, and more.
Nutritional Outlook and its sister publication Cannabis Science and Technology are pleased to launch a free, live, five-part editor’s webcast series titled “CBD: The Road to Quality.”
This unique series will take place during 2021, leveraging the expertise of these industry-leading publications and delivering insight and best practices on critical issues such as cultivation, extraction, processing, testing, third-party certifications, and much more.
Quality control is a crucial problem in the hemp cannabidiol (CBD) market. The quality gap is widening as more products enter the space. Government regulators, industry critics, and responsible market players understand many products in the market are failing to meet label claims. As competition grows in the CBD market, and as industry scrutiny increases, responsible companies must stand out by ensuring they employ industry best practices for putting credible, high-quality products on the shelf.
The first webcast, “Controlling THC Content,” kicks off on Tuesday, March 16, 2021, at 3 PM EDT / 2 PM CDT / 12 PM PDT. During this session, hemp cultivation experts will explore the best practices and methods for controlling tetrahydrocannabinol (THC) content. Experts will also provide an update on the legal landscape and challenges facing the industry.
“CBD: The Road to Quality” webcast series programs and dates are as follows:
Details on upcoming sessions will be announced in the next few months.
“Delivering direct access to trusted scientific news that is relevant and practical is key to our mission at MJH,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of Cannabis Science and Technology and Nutritional Outlook. “Together, with the expertise of Cannabis Science and Technology and Nutritional Outlook, we can provide those making and selling CBD products with the tools they need to ensure the quality of their products. Join us as we tap into the expertise of the CBD industry’s leading players and advisers.”
For more information and to register, click here.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.